Peter Thall

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
  2. doi request reprint A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
  3. pmc Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes
    Peter F Thall
    Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Biopharm Stat 22:785-801. 2012
  4. ncbi request reprint A review of phase 2-3 clinical trial designs
    Peter F Thall
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Lifetime Data Anal 14:37-53. 2008
  5. ncbi request reprint Practical model-based dose-finding in phase I clinical trials: methods based on toxicity
    P F Thall
    Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 13:251-61. 2003
  6. ncbi request reprint Dose-finding with two agents in Phase I oncology trials
    Peter F Thall
    Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Biometrics 59:487-96. 2003
  7. ncbi request reprint Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring
    Peter F Thall
    Department of Biostatistics, University of Texas, Houston, TX, USA
    Stat Med 26:4687-702. 2007
  8. ncbi request reprint Dose-finding based on efficacy-toxicity trade-offs
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 60:684-93. 2004
  9. ncbi request reprint Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments
    Peter F Thall
    Department of Biostatistics, Box 447, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, U S A
    Stat Med 24:1947-64. 2005
  10. ncbi request reprint Monitoring event times in early phase clinical trials: some practical issues
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Trials 2:467-78. 2005

Research Grants

  1. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter F Thall; Fiscal Year: 2010
  2. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter Thall; Fiscal Year: 2002
  3. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter Thall; Fiscal Year: 2006

Detail Information

Publications78

  1. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  2. doi request reprint A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
    ..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
  3. pmc Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes
    Peter F Thall
    Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Biopharm Stat 22:785-801. 2012
    ..The method is illustrated by a Phase I/II trial of radiation therapy for children with brainstem gliomas...
  4. ncbi request reprint A review of phase 2-3 clinical trial designs
    Peter F Thall
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Lifetime Data Anal 14:37-53. 2008
    ..A general conclusion is that, in many circumstances, a properly designed phase 2-3 trial utilizes resources much more efficiently and provides much more reliable inferences than conventional methods...
  5. ncbi request reprint Practical model-based dose-finding in phase I clinical trials: methods based on toxicity
    P F Thall
    Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 13:251-61. 2003
    ..The comparisons show that the Bayesian methods are much more reliable than the conventional algorithm for selecting an MTD, and that they have a low risk of treating patients at unacceptably toxic doses...
  6. ncbi request reprint Dose-finding with two agents in Phase I oncology trials
    Peter F Thall
    Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Biometrics 59:487-96. 2003
    ..A method for eliciting the single-agent parameter priors is described. The design is applied to a trial of gemcitabine and cyclophosphamide, and a simulation study is presented...
  7. ncbi request reprint Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring
    Peter F Thall
    Department of Biostatistics, University of Texas, Houston, TX, USA
    Stat Med 26:4687-702. 2007
    ..Advantages and disadvantages of this design compared to standard methods are discussed...
  8. ncbi request reprint Dose-finding based on efficacy-toxicity trade-offs
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 60:684-93. 2004
    ..Computer simulations show that, under a wide rage of dose-outcome scenarios, the new method has high probabilities of making correct decisions and treats most patients at doses with desirable efficacy-toxicity trade-offs...
  9. ncbi request reprint Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments
    Peter F Thall
    Department of Biostatistics, Box 447, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, U S A
    Stat Med 24:1947-64. 2005
    ..The adaptive randomization procedure generalizes the method proposed by Thompson (1933) for two binomial distributions with beta priors. A simulation study of the design in the context of the sarcoma trial is presented...
  10. ncbi request reprint Monitoring event times in early phase clinical trials: some practical issues
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Trials 2:467-78. 2005
    ..In such settings, it often is more natural to construct early stopping rules based on time-to-event variables. This type of design may involve a variety of complications, however...
  11. ncbi request reprint A geometric approach to comparing treatments for rapidly fatal diseases
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Biometrics 62:193-201. 2006
    ..Posterior probabilities of this set are used to construct rules for the treatment comparison and safety monitoring. The method is illustrated by a randomized trial comparing two cord blood transplantation methods...
  12. ncbi request reprint Some ethical issues in phase II trials in acute leukemia
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Adv Hematol Oncol 3:943-8. 2005
    ..The general conclusions are that statistical designs have both scientific and ethical implications, and that science, statistics, and ethics cannot be treated as separate issues...
  13. doi request reprint Bayesian designs to account for patient heterogeneity in phase II clinical trials
    Peter F Thall
    Department of Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Curr Opin Oncol 20:407-11. 2008
    ..The second design uses a hierarchical model for settings where, a priori, the experimental treatment effects in the subgroups are assumed to be exchangeable...
  14. ncbi request reprint Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, Houston, USA
    J Biopharm Stat 16:623-38. 2006
    ..To illustrate how the method may work in practice, we present a cohort-by-cohort example of a particular trial. We close with a discussion of some practical issues that may arise during implementation...
  15. pmc Practical Bayesian adaptive randomisation in clinical trials
    Peter F Thall
    Department of Biostatistics, Box 447, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Eur J Cancer 43:859-66. 2007
    ..The method will first be illustrated by a simple hypothetical example, then by a recent trial in which patients with unresectable soft tissue sarcoma were adaptively randomised between two chemotherapy regimens...
  16. doi request reprint Patient-specific dose finding based on bivariate outcomes and covariates
    Peter F Thall
    Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 64:1126-36. 2008
    ..The method is illustrated by a dose-finding trial in acute leukemia, including a simulation study...
  17. ncbi request reprint Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and ce
    P F Thall
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 33:1191-9. 2004
    ..For these patients, the posterior probability that i.v.BuCy2 was superior to alternative conditioning regimens ranges from 0.54 to 0.99, depending on prognosis and the magnitude of the assumed center effect...
  18. ncbi request reprint Ethical issues in oncology biostatistics
    Peter F Thall
    Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Stat Methods Med Res 11:429-48. 2002
    ..I describe particular experiences and the ethical issues involved. Topics include medical decision making, benefit-harm trade-offs, safety monitoring, adaptive randomization, informed consent, and publication bias...
  19. ncbi request reprint Adaptive decision making in a lymphocyte infusion trial
    Peter F Thall
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 58:560-8. 2002
    ..A simulation study shows that the design reliably selects the best infusion time while randomizing greater proportions of patients to superior infusion times...
  20. pmc Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies
    Peter F Thall
    Department of Biostatistics, M D Anderson Cancer Center, Houston, TX, U S A
    Stat Med 30:1777-94. 2011
    ..The methods are illustrated by a data set arising from 224 pediatric brain tumor patients treated with over 27 different chemo combinations involving seven chemo agents...
  21. ncbi request reprint Dose-finding based on feasibility and toxicity in T-cell infusion trials
    P F Thall
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Biometrics 57:914-21. 2001
    ..The method is illustrated by application to a dendritic cell activated lymphocyte infusion trial in the treatment of acute leukemia. A simulation study indicates that the proposed methodology is both safe and reliable...
  22. pmc Optimizing the concentration and bolus of a drug delivered by continuous infusion
    Peter F Thall
    Department of Biostatistics, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 67:1638-46. 2011
    ..The methodology is illustrated by a trial in which tissue plasminogen activator is infused intraarterially as rapid treatment for acute ischemic stroke...
  23. ncbi request reprint Optimal two-stage designs for clinical trials based on safety and efficacy
    P F Thall
    Department of Biostatistics, Box 447, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Stat Med 20:1023-32. 2001
    ..A more general group-sequential version of the design also is described, an illustration is provided, and application to the special case of single-arm phase II trials is discussed...
  24. ncbi request reprint Accrual strategies for phase I trials with delayed patient outcome
    P F Thall
    Department of Biomathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Stat Med 18:1155-69. 1999
    ..Based on our results, we provide practical guidelines for deciding among these approaches and strategies in a given clinical setting...
  25. ncbi request reprint Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
    ..To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa...
  26. ncbi request reprint Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes
    Peter F Thall
    Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Stat Med 22:763-80. 2003
    ..The applications illustrate how the hierarchical Bayesian model borrows strength across subtypes...
  27. ncbi request reprint Determining a maximum-tolerated schedule of a cytotoxic agent
    Thomas M Braun
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, USA
    Biometrics 61:335-43. 2005
    ....
  28. ncbi request reprint Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens
    Peter F Thall
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 99:1613-22. 2007
    ..With the goal of efficiently selecting promising regimens for more advanced trials, we conducted a randomized selection trial of four regimens to identify promising treatments for androgen-independent prostate cancer...
  29. doi request reprint Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:474-80. 2013
    ..017); and overall survival, 27% versus 9% (P = .02). We conclude that optimizing i.v. busulfan dose intensity in the preparative regimen may overcome disease-associated poor prognostic factors...
  30. doi request reprint High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    ..In conclusion, gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials...
  31. ncbi request reprint Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer
    Randall Millikan
    Genitourinary Medical Oncology Department, University of Texas M D Anderson Cancer Center, Houston, TX 77040 4009, USA
    J Clin Oncol 21:878-83. 2003
    ..We used a randomized phase II design to evaluate and compare two such regimens. Patients were accrued primarily in the community setting...
  32. ncbi request reprint A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:758-65. 2002
    ..Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis...
  33. ncbi request reprint Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies
    Shifeng Mao
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Prostate 67:1677-85. 2007
    ....
  34. ncbi request reprint Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:561-7. 2003
    ....
  35. ncbi request reprint Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission
    Stefan Faderl
    Department of Leukaemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Haematol 117:869-74. 2002
    ..We conclude that a quicker TPR predicts longer DFS and OS in patients with ALL. As platelet counts are obtained almost daily in patients undergoing chemotherapy, TPR can readily be utilized to assess the prognosis of these patients...
  36. doi request reprint Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia
    Paul M Armistead
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston Texas, USA
    Biol Blood Marrow Transplant 15:1431-8. 2009
    ..Our data suggest that HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years...
  37. ncbi request reprint Continuous Bayesian adaptive randomization based on event times with covariates
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Stat Med 25:55-70. 2006
    ..We illustrate these methods by application to a phase II selection trial in acute leukaemia. A simulation study in the context of this trial is presented...
  38. ncbi request reprint Seamlessly expanding a randomized phase II trial to phase III
    Lurdes Y T Inoue
    Department of Biostatistics, University of Washington, Box 357232, Seattle, Washington 98195, USA
    Biometrics 58:823-31. 2002
    ....
  39. ncbi request reprint Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes
    Janice N Cormier
    Sarcoma Center and Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4567-74. 2004
    ..The role of chemotherapy for these patients remains controversial despite several randomized trials and a meta-analysis...
  40. ncbi request reprint Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center
    Johannes E Wolff
    Department of Pediatrics, M D Anderson Cancer Center, Houston, TX, USA
    Anticancer Res 31:2265-9. 2011
    ..The biology of diffuse intrinsic pontine glioma remains poorly understood and the dismal prognosis has not changed despite various attempts to add chemotherapy to standard radiation...
  41. doi request reprint Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 181:81-7; discussion 87. 2009
    ..Men with high risk localized prostate cancer were treated with platelet derived growth factor receptor inhibitor therapy, docetaxel and hormone ablation in the preoperative setting, and clinicopathological outcomes were evaluated...
  42. pmc Monitoring late-onset toxicities in phase I trials using predicted risks
    B Nebiyou Bekele
    Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Biostatistics 9:442-57. 2008
    ..This advantage increases with accrual rate, but the price of this additional safety is that the trial takes longer to complete on average...
  43. doi request reprint Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
    Marcos de Lima
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5420-31. 2010
    ..The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination...
  44. doi request reprint Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
    Biol Blood Marrow Transplant 14:672-84. 2008
    ..These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1...
  45. doi request reprint Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 21:S11-5. 2009
    ....
  46. pmc Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:3851-7. 2010
    ..We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy...
  47. doi request reprint Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:2592-7. 2009
    ..We now report results from the first phase II clinical trial developed exclusively for SCUC, to our knowledge...
  48. doi request reprint Bayesian adaptive model selection for optimizing group sequential clinical trials
    J Kyle Wathen
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, U S A
    Stat Med 27:5586-604. 2008
    ....
  49. doi request reprint A possible association between aprotinin and improved survival after radical surgery for mesothelioma
    Peter H Norman
    Department of Anesthesiology and Pain Medicine, Unit 409, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 115:833-41. 2009
    ..In this prospective, randomized, placebo-controlled, double-blind trial, the authors investigated whether aprotinin decreased blood loss in patients who underwent this operation...
  50. ncbi request reprint Accounting for patient heterogeneity in phase II clinical trials
    J Kyle Wathen
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Stat Med 27:2802-15. 2008
    ..A simulation study is presented and the method is illustrated by a chemotherapy trial in acute leukemia...
  51. ncbi request reprint Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas
    Peter W T Pisters
    Multidisciplinary Sarcoma Center, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030 4009, USA
    J Clin Oncol 22:3375-80. 2004
    ....
  52. ncbi request reprint Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:3323-9. 2004
    ..Our goals were to (1) evaluate the toxicity and maximum-tolerated dose of docetaxel with imatinib, and (2) evaluate the decline of prostate-specific antigen (PSA) induced by imatinib alone, and imatinib and docetaxel...
  53. ncbi request reprint Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    Marcos de Lima
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:857-64. 2004
    ..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT...
  54. ncbi request reprint Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia
    Borje S Andersson
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77005, USA
    Biol Blood Marrow Transplant 8:477-85. 2002
    ..Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation...
  55. ncbi request reprint New designs for phase 2 clinical trials
    Elihu H Estey
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:442-8. 2003
    ..These concerns motivated the development of a general paradigm for randomized selection trials evaluating several therapies based on multiple outcomes. Three illustrative applications of trials using this approach are presented...
  56. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  57. ncbi request reprint Simultaneously optimizing dose and schedule of a new cytotoxic agent
    Thomas M Braun
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
    Clin Trials 4:113-24. 2007
    ..Consequently, the overall risk of toxicity for each patient is a function of both actual schedule of treatment and the differing doses used at each adminstration...
  58. ncbi request reprint Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:4343-9. 2002
    ..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
  59. ncbi request reprint Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:3097-9. 2003
    ..0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML...
  60. doi request reprint Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:412-20. 2011
    ..Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies...
  61. pmc Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer
    Dimitra Tsavachidou
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:306-20. 2009
    ....
  62. doi request reprint High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Transplantation 88:1019-24. 2009
    ..Anti-HLA sensitization should be evaluated routinely in hematopoietic stem-cell transplantation with HLA mismatched donors...
  63. ncbi request reprint Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 11:108-14. 2005
    ....
  64. ncbi request reprint Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate
    Dejka M Steinert
    Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer 106:1617-23. 2006
    ..To the authors' knowledge, the current study is the first to evaluate Bcl-2 expression in pre-imatinib GIST tissue samples as a prognostic marker of progression-free survival (PFS) time in patients treated with imatinib...
  65. ncbi request reprint Monitoring the rates of composite events with censored data in phase II clinical trials
    Ying Kuen Cheung
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Biometrics 58:89-97. 2002
    ..Application to a leukemia trial with a composite event shows that the method can reduce trial duration substantially while maintaining the reliability of interim decisions...
  66. ncbi request reprint Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate
    John C McAuliffe
    Department of Sarcoma Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 13:6727-34. 2007
    ..Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression...
  67. pmc A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301438, Houston, TX 77030, USA
    Cancer 116:814-21. 2010
    ..This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules...
  68. doi request reprint Durable remission with salvage second autotransplants in patients with multiple myeloma
    Nina Shah
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3549-55. 2012
    ..However, the role of salvage auto-HCT for relapsed patients, particularly in the era of novel therapeutics, is not well defined...
  69. ncbi request reprint A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression
    Francis J Giles
    Department of Leukaemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 121:578-85. 2003
    ....
  70. doi request reprint A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis
    John C McAuliffe
    The University of Texas Houston, Houston, TX, USA
    Ann Surg Oncol 16:910-9. 2009
    ..02). Imatinib appears to be safe and may be considered for patients undergoing surgical resection of their GIST. Radiographic response and tumor cell apoptosis occur within the first week of imatinib therapy...
  71. ncbi request reprint Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers
    Jon R Wiener
    Department of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Gynecol Oncol 88:73-9. 2003
    ..The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers...
  72. ncbi request reprint Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
    Fadlo R Khuri
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:2968-76. 2004
    ....
  73. ncbi request reprint Some ethical issues in phase II trials in acute leukemia
    Peter F Thall
    Clin Adv Hematol Oncol 4:95. 2006
  74. doi request reprint Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
    Harry T Whelan
    Division of Pediatric Neurology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA
    Stroke 39:2627-36. 2008
    ..This article describes a Bayesian outcome-adaptive method for determining the best dose of an experimental agent and explains how this method was used to design a dose-finding trial for tPA in childhood...
  75. ncbi request reprint Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  76. pmc Determining the effective sample size of a parametric prior
    Satoshi Morita
    Department of Epidemiology and Health Care Research, Kyoto University Graduate School of Medicine, Kyoto 606 8501, Japan
    Biometrics 64:595-602. 2008
    ..We provide general guidelines for application, illustrate the method in several standard cases where the answer seems obvious, and then apply it to some nonstandard settings...
  77. ncbi request reprint Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit
    Borje S Andersson
    Biol Blood Marrow Transplant 9:722-4. 2003
  78. ncbi request reprint Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system
    Peter H Shaw
    Department of Pediatrics, University of Pittsburgh School of Medicine and Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213 2583, USA
    Biol Blood Marrow Transplant 9:151-6. 2003
    ..Our ex vivo expansion technique needs to be further optimized before it can be used in a pilot UCB transplantation trial...

Research Grants8

  1. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter F Thall; Fiscal Year: 2010
    ....
  2. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter Thall; Fiscal Year: 2002
    ..The aim is to provide a basis for safety monitoring in phase III trials that is part of the formal test, rather than an additional ad hoc procedure. ..
  3. STATISTICAL METHODS FOR COMPLEX CANCER TRIALS
    Peter Thall; Fiscal Year: 2006
    ..In order to promulgate the methods to the statistical and medical communities, user-friendly computer software for implementation will be made freely available. ..